Microbioz India, November 2023| 1
Microbioz India, November 2023| 2
Microbioz India, November 2023| 3
Microbioz India, November 2023| 4
Microbioz India, November 2023| 5
Microbioz India, November 2023| 6 16 20 10 18 14 10 18 Cover Story Revolutionizing Diagnosis: The Role of Advanced Radiology Featured Article Understanding the Role of Pediatric Associates in Your Child's Health Business News MTaI Bats for Fans Well-being: 'No Boundaries’ for Safety in Cricket! Product Launches Lab-on-a-Chip Genetic Test Device Identifies Viruses in Three Minutes 10 12 28 33
Microbioz India, November 2023| 7
Microbioz India, November 2023| 8 Disclaimer: Neither the Microbioz India nor its publishers nor anyone else involved in creating, producing or delivering the Microbioz India (in printed, web or CD format) or the materials contained therein, assumes any liability or responsibility for the accuracy, completeness, or usefulness of any information provided in the Microbioz India Magazine (in printed, web or CD format), nor shall they be liable for any direct, indirect, incidental, special, consequential or punitive damages arising out of the use of the Microbioz India magazine. ear Readers, Welcome to the latest issue of Microbioz India-Healthcare and Diagnostic special edition. It's a true pleasure to have you with us once again, and we hope you find this edition as captivating and inspiring as ever. In this issue, we're thrilled to delve into the intriguing world of Revolutionizing Diagnosis: The Role of Advanced Radiology our cover story of the month. Our team has worked tirelessly to curate content that we believe will both entertain and enlighten you, from thought-provoking features to stunning visuals that capture the essence of our chosen theme. We are excited to showcase some incredible contributors, whose expertise and creativity have graced the pages of this magazine. Their passion for digital healthcare and innovation shines through in every article, photograph, and piece of art. Be sure to check out our special product showcase section, where you'll find latest product launches and stories. It's a testament to our commitment to providing you, our readers, with diverse and engaging content. As always, Microbioz India is a reflection of our dedication to delivering top-quality journalism, exquisite design, and stories that resonate with you. We're immensely grateful for your continued support and readership, which drives us to keep raising the bar. We encourage you to connect with us through our social media channels, where you can share your thoughts, feedback, and suggestions. Your voices are what inspire and guide us in our mission to bring you a magazine that truly speaks to your interests and passions. Thank you for choosing to spend your time with us. We hope you thoroughly enjoy this issue and that it leaves you inspired, informed, and entertained. Enjoy the read!
Microbioz India, November 2023| 9
Microbioz India, November 2023| 10 Revolutionizing Diagnosis: The Role of Advanced Radiology ifferent diseases have been revolutionized by advanced radiology. Technological advancements have brought about increased accuracy, speed, and non-invasiveness in medical imaging in this field. Advanced radiology is changing the face of healthcare in the following ways: Early Disease Detection: Early illness detection can also be achieved by the use of positron emission tomography (PET), magnetic resonance imaging (MRI), and computed tomography (CT). This is the reason these new techniques are significant since they aid in determining the best course of action for each patient before they receive a full recovery. Precision Medicine: Radiomics is one part of radiology that focuses on extracting and analyzing quantitative features from medical images. This way the radiomics features helps to develop individual treatment strategies which may lead to more personalized medicine. D Cover Story
Microbioz India, November 2023| 11 Minimally Invasive Procedures: Angioplasty, embolization, image-guided biopsies some examples of interventional radiology procedures that have significantly changed patient care. These minimally invasive techniques use stateof-the-art imaging to guide surgeons and interventional radiologists thereby eliminating open surgery requirement as well as reducing recovery time. Cancer Diagnosis and Staging: Significant impact on cancer diagnosis, staging, and treatment planning has been made by advanced radiology. For instance, with such a radiologist oncologist can determine the size, location as well as extent of tumours. Neuroimaging: Neuroimaging techniques such as functional MRI (fMRI) and diffusion tensor imaging (DTI) are used to explain neurological conditions such as Alzheimer’s disease; Parkinson’s disease; traumatic brain injuries e.g fMRI and Ditherer this helps in identifying how the brain functions before any treatment plan is made for instance diagnosing brain structure/function prior to treatment plan this would include some examples including functional MRI (fMRI) or diffusion tensor imaging (DTI). Cardiovascular Imaging: It covers coronary CT angiography or cardiac MRI scanning that allows assessment of heart/vessel conditions without invasive methods. These situations enable early detection of coronary artery disease like congenital heart defects among others during their early stages. 3D and 4D Imaging: 3D & 4D imaging techniques are used to see a patient’s anatomy and pathology better. This is especially useful in complex surgeries as well as treatment planning. Telemedicine and Remote Consultations: Advanced radiology enables telemedicine and remote consultations where specialists can review medical images from anywhere around the world. This is particularly important in areas without access to healthcare resources. Machine Learning and AI: Application of artificial intelligence (AI) as well as machine learning algorithms are being applied to medical imaging systems so as to enhance diagnostic accuracy, speed, and efficiency. These algorithms have potential to aid radiologists in identifying and characterizing abnormalities in images which might reduce human errors thus speeding-up diagnostic process. Quantitative Imaging Biomarkers: Radiology is increasingly being used to measure a range of biomarkers associated with disease progression and treatment response. Monitoring patient outcomes through this quantitative data can be helpful for adjusting treatment plans accordingly. Healthcare providers have been able to diagnose patients better due to advanced radiology, resulting into early detection, accurate interventions, and improved patient outcomes. Radiology will continue playing a significant role towards revolutionizing healthcare diagnosis/treatment even more as technology keeps advancing. Cover Story
Microbioz India, November 2023| 12 Understanding the Role of Pediatric Associates in Your Child's Health he role of pediatric associates in children’s healthcare is very important. They are doctors who provide comprehensive health care to newborns, infants, children, and young adults. Role of Pediatric Associates in Your Child’s Health: Primary Care Providers: Pediatric associates are primary care providers for children. They have the knowledge to treat and diagnose a wide range of medical conditions that affect children which include chronic diseases, colds, ear infections and developmental issues. Well-Child Care: Pediatricians and pediatric associates provide regular well-child visits. This includes performing routine checks and assessments to track growth and development, administering vaccinations according to immunization schedules and giving advice on nutrition, safety and developmental milestones. Preventive Care: With the aim of keeping children healthy, pediatric associates concentrate on preventive care. They guide parents on ways through which they can maintain a healthy lifestyle such as recommendations on healthy diets balanced diet, exercising regularly as well as good hygiene at all times. Also, they offer anticipatory guidance for mothers about childproofing their homes by ensuring safety measures are put in place against potential injuries. Diagnosis and Treatment: When your child is sick or suffers from any medical condition, pediatric associates can make proper diagnoses and give appropriate treatment. That means they can prescribe drugs; ask for laboratory tests as well as referral patients to specialists when required thereby making treatment options best suit individual needs of kids. T Featured Article
Microbioz India, November 2023| 13 Developmental and Behavioral Assessments: Pediatricians and pediatric associates also have expertise in evaluating the developmental and behavioral aspects of child health. They monitor your child’s milestones while watching out for any delays or concerns occurring early in life. Furthermore, they also provide counseling for these ailments like ADHD (Attention Deficit Hyperactivity Disorder), autism spectrum disorders (ASD)’ emotional problems. Family-Centered Care: Pediatric associates understand that family plays a significant role when it comes to the health status of a child. In most cases, they work closely with parents and caretakers whereby they involve them in decision making about health, as well as provide education and resources that can enhance their child’s health. Continuity of Care: Pediatricians and pediatric associates are often involved in long-term relationships with patients and families. This continuity enables them to provide individualized and consistent healthcare for children throughout their growth and development thereby facilitating earlier intervention of any emerging health issues or concerns. Advocacy: Pediatric associates advocate for children’s healthcare both at an individual level and within the community. They may be involved in public health campaigns; cooperate with other groups concerned with child health policies; or lobby for improvements in pediatric healthcare services. In short, the work done by pediatric associates is critical in ensuring that children remain healthy or get well from illnesses. They are indispensable partners in ensuring that your child has a quality medical care system starting from infancy till adolescence due to their specialized training for child health. Establishing trust and strong relationships with the child’s pediatrician will contribute towards healthier outcomes which will lead to meaningful healthcare experiences for you as a family. Featured Article
Microbioz India, November 2023| 14 Understanding Neonatal Immersion Photography: A Visual Journey eonatal immersion photography, also known as neonatal underwater photography, is a specialized form of photography that captures the beauty and fragility of newborn babies in a unique and artistic way. This photography requires immersing babies in water while at the same time capturing images of them floating or submerged. The following is an overview of what neonatal immersion photography entails: Artistic Expression: When it comes to newborns, neonatal immersion photography represents one form of artistic expression that aims to capture their innocence and vulnerability. Often, these photos are ethereal and dreamlike, emphasizing on the purity of the baby. Safety and Expertise: In this field of neonatal immersion photography, safety is highly regarded. Photographers specializing in this niche must be well trained and experienced in handling infants under water because they know how to take care of them during the process. Warm Water: To ensure comfort for the baby, warm water is used for neonatal immersion photography. The temperature can be adjusted to resemble that inside a mother’s womb in order to soothe an infant’s skin. Controlled Environment: This ensures that the infant is safe. The photographer controls all aspects of photo session being held in a studio or specially constructed pool with shallow waters. They will not leave him alone unless he starts swimming by himself. N Featured Article
Microbioz India, November 2023| 15 Posing and Composition: To result in eye-catching scenes, photographers should place a child in various postures near water bodies like pools. At different angles within water such as straight up floating ones, curled up positions or posing reaching out may be used. Natural Light: To have soft and gentle atmosphere on their shots; most photographers use natural light when shooting newborns immersed under water. This makes it look better aesthetically speaking besides giving them warm inviting feeling when you see them. Parental Involvement: Sometimes parents are involved into photo shoot directly standing close to their child with photographer taking images that are more intimate and emotional. Post-Processing: These artistic photos will usually be edited after taking them. For example, their color balance, retouching and other effects can be altered depending on the preferences of the artist. Emotional Impact: What neonatal immersion photography does is make people feel emotional when they see these pictures. They all often carry emotions of awe, tenderness as well as preciousness of life. Ethical Considerations: Whenever people engage in neonatal immersion photography, there are ethical and consent concerns that photographers and parents need to be mindful of. Since baby’s safety matters most of all. In general, neonatal immersion photography is an exclusive artistic way to capture infants’ early stages of growth. These images may lead to stunning and emotionally persuasive photographs that celebrate the beauty and delicacy of infancy. Therefore, if parents find it useful for them to have such kind of pictures taken by a photographer who has experience in handling newborns, then they should ensure that the child’s comfort and safety are considered first at all times. Featured Article
Microbioz India, November 2023| 16 Mastering in Situ Hybridization: Tips and Best Practices he method known as in situ hybridization (ISH) holds significant prowess within the realm of molecular biology. It serves as a formidable tool for detecting and visually representing distinct nucleic acid sequences within cells or tissues. Esteemed for its application in research and diagnostics, ISH enables the study of gene expression, identification of viral or bacterial infections, and exploration of chromosomal irregularities. To achieve mastery in the art of in situ hybridization, one must adhere to various tips and best practices: 1. Diligently Plan Your Experiment: Before embarking on your journey, devise a meticulously crafted experimental design. Clearly define your research objectives, select the appropriate probe (DNA or RNA), and carefully choose your target tissue or cells. 2. Optimize Probe Design: It is imperative to ensure that your probe specifically targets the desired nucleic acid sequence. Factors such as probe length, GC content, and secondary structure should be taken into consideration. The utilization of probe design software can greatly aid in optimizing this process. 3. Strategically Label Your Probe: Enhance the visibility of your probe by labeling it with a reporter molecule such as fluorescein, biotin, or digoxigenin. Choose a labeling method that aligns with your experimental needs—options include radioactive labeling, enzymatic labeling, or fluorescent labeling. 4.Employ Positive and Negative Controls: Validate your findings and address potential issues by incorporating both positive controls (samples containing known expression of the target sequence) and negative controls (samples devoid of the target sequence). T Featured Article
Microbioz India, November 2023| 17 5. Give Importance to Tissue Preparation: Proper preparation of tissue is paramount to successful outcomes. Ensure that your tissue is adequately fixed, sectioned, and mounted on slides. The efficacy of probe penetration and target accessibility can be influenced by proper tissue fixation. 6. Execute Prehybridization Treatment: Prepare the tissue for probe hybridization through prehybridization treatments. This may involve steps such as proteinase K digestion, acetylation, and dehydration. 7. Fine-tune Hybridization Conditions: Achieving optimum hybridization conditions, including temperature, time, and buffer composition, is crucial. Stringency must be carefully balanced to ensure specific binding of the probe to the target sequence. 8. Determine Probe Concentration: Employ titration to ascertain the ideal probe concentration for your experiment. An excess of probe can result in background noise, while insufficient quantities may yield weak signals. 9. Implement Wash Stringency: To eliminate unbound probes and minimize background signal, meticulous post-hybridization washing is necessary. Gradually decreasing the stringency of washes will help identify the optimal conditions for precise hybridization. 10. Select an Appropriate Detection Method: The choice of a detection method should align with your probe label—for instance, fluorescence, colorimetric, or chemiluminescence. Each method possesses distinct advantages and limitations. 11. Employ Counterstaining Techniques: Utilize counterstains (such as DAPI, hematoxylin, eosin) when necessary to visualize cell nuclei or tissue structures alongside the ISH signal. 12. Utilize Microscopy and Imaging Tools: Capture high-quality images of your ISH samples through the use of a fluorescence or brightfield microscope equipped with suitable filters and imaging software. 13. Analyze Your Data: Employ appropriate image analysis software or tools to analyze and quantify your ISH results. Measure signal intensity, location, and distribution as required. 14. Maintain Detailed Documentation: Keep comprehensive records of your ISH experiments—protocols, images, and results—in order to ensure reproducibility and facilitate troubleshooting if necessary. 15. Be Prepared for Troubleshooting: Anticipate common issues such as high background noise, weak signal intensity, or non-specific binding. Systematically adjust experimental conditions to address these challenges. 16. Practice and Cultivate Patience: In situ hybridization can prove to be a technically demanding technique. Dedicate time to practice and exercise patience as you strive for mastery. Seek guidance from experienced researchers or mentors when needed. Remember that achieving proficiency in in situ hybridization may require multiple iterations and optimization steps tailored to your specific experiment. Featured Article
Microbioz India, November 2023| 18 SMART researchers pioneer novel microfluidic method to optimise bone marrow stem cell extraction for advanced cell therapies 1. Traditional bone marrow aspirate (BMA) stem cell extraction methods are complex, timeconsuming, and yield poor results due to antiquated centrifugation techniques 2. SMART’s new method of isolating stem cells from BMA is simpler and ten times faster, resulting in twice as efficient enrichment of mesenchymal stem cells 3. The technology also enables faster drug production in cell therapy manufacturing, while bone marrow donors benefit from shorter aspiration processes esearchers from the Critical Analytics for Manufacturing Personalized-Medicine (CAMP) Interdisciplinary Research Group (IRG) of Singapore-MIT Alliance for Research and Technology (SMART), MIT’s research enterprise in Singapore, in collaboration with the Agency for Science, Technology and Research (A*STAR) Bioprocessing Technology Institute (BTI) and National University Health System (NUHS), have developed a groundbreaking technology capable of extracting mesenchymal stem cells (MSCs) directly from pure bone marrow – also known as bone marrow aspirate (BMA), a pivotal source of MSCs – without dilution. Using a world-first continuous sorting technique on a multi-chip Deterministic Lateral Displacement (DLD) microfluidic platform, the new method doubles the quantity of MSCs obtained from bone marrow samples and shortens the time taken to around 20 minutes. It also reduces donor discomfort due to less bone marrow being extracted, speeds up cell production, and simplifies cell therapy manufacturing. This advancement represents a significant step toward more accessible and efficient advanced medical treatments that use MSCs – including treatment for osteoarthritis, autoimmune and infectious diseases, and neurological disorders. Cell therapy is a field of medicine where cells are used as living drugs to fight diseases or restore and replace damaged cells. Advances in regenerative medicine and immunotherapy have benefited countless patients; they offer numerous new treatment alternatives to previously intractable diseases, with hundreds more in the developmental pipeline that gives new hope to patients. R Guest Post
Microbioz India, November 2023| 19 However, obtaining high-quality raw materials – in this case, MSCs – has long been a hurdle in cell therapy manufacturing, as traditional isolation methods such as centrifugation are inefficient and complex. In addition to a long processing time of around two to three hours, current methods result in low yield due to challenges such as osmotic stress and complex workflows. State-of-the-art sorting techniques such as fluorescence-activated cell sorting (FACS) rely on costly antibodies and intricate preparation, posing major limitations for manufacturing of these living medicines. In a paper titled “Scalable mesenchymal stem cell enrichment from bone marrow aspirate using DLD microfluidic sorting”, recently published in the journal Lab on a Chip, SMART researchers have pioneered a revolutionary stem cell sorting platform, addressing the challenges of large-scale cell sorting and manufacturing. Using DLD microfluidic technology, a label-free cell sorting method which distinguishes between stem cells and blood cells, the platform processed small bone marrow samples (2.5mL) in just 20 minutes with double the stem cell yield compared to traditional methods, and bypasses costly reagents and complex processes. In this method pioneered by SMART, human bone marrow samples that arrive at the laboratory undergo a simple filtration step to remove unwanted cells and tissues that could obstruct the chip. Samples are then loaded onto SMART’s sorting platform, and cells of interest (MSCs) are automatically sorted and collected in outlet reservoirs. These collected cells are then combined into a vial for further processing and quantification as needed. This innovative breakthrough in cell sorting utilises microfluidic technologies, leveraging cells' natural properties and eliminating the necessity for labelling. With conventional methods, cells are sorted using fluorescent or magnetic tags to label certain cellular features. This is challenging as these labels could interfere with subsequent analysis and testing, or worse damage the cells. In comparison, passive techniques like the DLD method developed at SMART are user-friendly, gentle on cells and easily integrated into clinical sample processing workflows. MSCs are very sensitive to its external environment, and perturbations could alter the biology in unanticipated ways. "This novel platform provides a fresh perspective for stem cell sorting through a more efficient, labelfree and, importantly, seamless process integration into current industrial manufacturing pipeline. Our research team at SMART is excited about the possibilities this technology brings to the field of stem cell research and therapy. The successful demonstration of this technology gives us greater confidence to venture into other bioprocessing applications such as leukopheresis with great potential for clinical impact. This will significantly accelerate the development of cutting-edge treatments and improve accessibility for cell therapy," said Mr Nicholas Tan, Research Engineer at SMART CAMP and lead author of the paper. “Even though DLD cell sorting has previously been demonstrated, what is new in this work is that we were able to deploy the technique at a sufficiently high processing flow rate to impact real-world stem cell manufacturing workflow. Biomanufacturing and bioprocessing are areas in which I see much potential for applying microfluidics technology to improve overall efficiency and reduce the cost significantly,” said Professor Jongyoon Han, CoLead Principal Investigator at SMART CAMP, Professor of Biological Engineering and Electrical Engineering at MIT and corresponding author of the paper. Future efforts will focus on refining the technology by evaluating the quality of sorted MSCs from human bone marrow samples using methods such as reverse transcription polymerase chain reaction (RT-PCR) and differentiation assays. Simultaneously, CAMP is working towards increasing sorting speed and resolution, while refining the system's design for portability and userfriendliness, and increasing throughput to 10 ml per minute. “Our innovative approach marks a paradigm shift in cell sorting, a key process of cell therapy. By harnessing microfluidic technologies to capitalise on cells' intrinsic properties, we have eliminated the need for cumbersome and expensive labelling methods. It not only streamlines the sorting process but also ensures more accurate and reliable results in medical research. This breakthrough, driven by our commitment to advancing scientific frontiers, heralds a milestone in the realm of cellular studies," said Dr Kerwin Kwek, Research Scientist at SMART CAMP and co-lead author of the paper. Guest Post
Microbioz India, November 2023| 20 Oasis Fertility, Karimnagar conducts Baby Shower to felicitate mothers-to-be who conceived through IVF nfertility is on a steady rise due to sedentary lifestyle, lack of sleep, obesity, delayed parenthood, PCOS, etc. Personalized fertility treatments can help fertility challenged couples to overcome infertility and become happy parents. Oasis Fertility, Karimnagar one of the trusted fertility chains in India offers advanced fertility treatments to help couples achieve their parenthood dream. The centre organized a mass baby shower to felicitate mothers-to-be who conceived through IVF. Dr Lalitha Devi (DMHO), and Dr Jigna Tamagond, Consultant Fertility Specialist, Oasis Fertility, Karimnagar; graced the occasion. Chief Guest Dr Lalitha Devi, DMHO; said, in Karimnagar we have 13 IVF clinics, I am a state ART committee member, and one of those who needs to give permission for IVF clinics in the state. I visited 10 clinics in Karimnagar, Oasis also got permission of ART level 2. 60% of young girls are suffering from hormonal balance, several of these due to lifestyle and change in food habits are needing infertility treatment. Congratulate Oasis team for their 73% success rate in the very first year of inception in Karimnagar, their Hyderabad, Warangal clinics are also highly successful. Quality of care and affordable treatment are important. Oasis has excellent infrastructure. Speaking on the occasion, Dr Jigna Tamagond, Consultant Fertility Specialist, Oasis Fertility, Karimnagar, stated “I congratulate all the mothersto-be who took the right decision at the right time that has helped them achieve parenthood. Fertility preservation is an advanced technique that can help women with cancer preserve their fertility and conceive later at their convenience. Through PGT (Pre-implantation Genetic Testing) and ERA (Endometrial Receptivity Array), we improve the success rate of IVF and also reduce the risk of miscarriage. We offer advanced techniques like MicroTESE (Microsurgical Testicular Sperm Extraction) to help men with zero sperm count achieve fatherhood”. ABOUT OASIS FERTILITY: Oasis Fertility, a unit of the Sadguru Healthcare Services Pvt. Ltd., has redefined reproductive care in India by bringing in internationally recognized best practices and protocols in Fertility treatments. It offers would-be parents a friendly ‘one-stop’ daycare clinic where consultations, investigations, and treatment are all conducted under one roof. Since its inception in 2009, Oasis has gained an excellent reputation for its high success rates driven by its high-quality services led by a team of experienced infertility specialists with international experience. The chain has expanded to 33+ centres across the states of Andhra Pradesh, Telangana, Tamil Nadu, Karnataka, Jharkhand, Gujarat, Maharashtra, Chhattisgarh and Odisha. L V Prasad Eye Institute (LVPEI) shines spotlight on refractive errors in children: the overlooked vision challenge I Hospital Watch
Microbioz India, November 2023| 21 1. As part of the Children's Eye Care Week (13-19 November), L V Prasad Eye Institute (LVPEI), through its dedicated Children's Eye Care Centres across its network, organizes various activities to raise awareness about refractive errors in children. 2. Uncorrected refractive error is one of the leading causes of blindness worldwide; 20% of India's total visually impaired population suffers from uncorrected refractive errors. 3. 1-3-5, Give Good Eye Sight: An eye examination at one, three, and five years is paramount to early diagnosis and treatment of refractive errors and other eye problems in Children. 4. LVPEI is organizing the Children's Eye Care Walk on Sunday, 19th November 2023, at 7:00 am, starting from its Kallam Anji Reddy Campus, Banjara Hills, Hyderabad. efractive errors occur due to natural differences in eyeball sizes, affecting how we process the images. To understand it, we can imagine our eye as a camera and the retina as its film – refractive errors occur when the eye's shape doesn't let light focus correctly on this "film" at the back of the eyes. Types of refractive errors include Myopia (nearsightedness), hypermetropia (farsightedness), and astigmatism (eye focus well in one direction). Children with these conditions often struggle with basic daily tasks. They may experience frequent headaches, eyestrain, and fatigue while reading and may even develop squint as they adapt to the refractive errors. Recent data underscores the global significance of uncorrected refractive errors, emerging as a leading cause of blindness. In India, this concern is starkly evident, with 20% of visually impaired individuals grappling with unaddressed refractive errors—an alarming statistic that demands urgent attention. Particularly, the escalating prevalence of Myopia paints a dire picture. Without proactive measures, projections indicate that nearly half of the world's population (5 billion) will be affected by 2050. The gravity of the situation is further highlighted in urban India, where an anticipated 48% of children may battle Myopia by 2050, transcending mere vision concerns to crystallize as a looming public health crisis. The reasons for the surge in refractive errors are complex. Genetics play a role, with a higher likelihood of Myopia if one or both parents have it. Environmental factors, such as prolonged nearwork, excessive screen time, and insufficient outdoor activities, predispose one to Myopia. Exposure to dust and smoke can cause eye allergies, and constant eye rubbing can increase the risk of astigmatism. The impact of these conditions on children is profound. Children adapt to their blurred vision, adjusting to close-range activities and avoiding tasks that require sharp focus, affecting their academic performance and taking a toll on their psychological well-being. Dr Rohan Nalawade, Pediatric Ophthalmologist at LVPEI Hyderabad, emphasizes the significance of recognizing tell-tale symptoms of refractive errors, urging immediate consultation with an eye specialist upon their observation. "These crucial indicators include reading or watching television at a close distance, experiencing difficulty in seeing the blackboard clearly at school, frequent headaches and eyestrain, and squeezing or squinting of the eyes. Ignoring these signs may compromise visual health, making early intervention imperative for optimal eye care." Diagnosis and Treatment of Refractive Errors: Eye examinations at one, three, and five years are paramount to diagnosing and treating refractive errors early. Thankfully, refractive errors are treatable with simple solutions like glasses or contact lenses. But, regular follow-ups to check for changes in glass prescription, treatment of lazy eye and treatment of progressive refractive errors are crucial to ensuring optimal vision. The following preventive measures can help in preventing refractive errors in our children: 1) Manage Screen Time: We encourage you to balance screen use and physical activities. A safe amount of screen time varies by age. Indian Academy of Pediatrics recommends that children below two years should not be exposed to any screen. Further, exposure should be limited to one hour of supervised screen time per day for children between two and under five years of age and less than two hours per day for children 6-10. 2) Encourage Outdoor Time: Children spending at least 60 minutes outdoors daily reduce their risk of Myopia by over 14%. Therefore, ophthalmologists promote outdoor play for overall well-being. R Hospital Watch
Microbioz India, November 2023| 22 3) Follow the 20-20-20 Rule: Break every 20 minutes of near work with a 20-second break, focusing on an object 20 feet away. It helps relieve eye strain and discomfort. 4) Optimal Reading Habits: Maintain a 15-inch distance and a 60-degree angle while reading. Ensure well-lit environments to prevent eye strain. “Undiagnosed and untreated refractive errors can lead to delayed milestones in children and negatively impact their academic performance, participation in co-curricular activities and social behaviour. Children with Myopia are at a higher risk of developing retinal detachment, glaucoma, cataract and other eye diseases. Some of these eye disorders can result in irreversible vision loss. Hence, it is the collective responsibility of families, teachers, doctors, healthcare organizations and government to ensure children’s health and well-being,” says Dr Ramesh Kekunnaya, Head, Child Sight Institute, L V Prasad Eye Institute. As part of Children's Eye Care Week, LVPEI invites you to participate in the Children's Eye Care Walk on Sunday, 19th November 2023, at 7:00 am, starting from its Kallam Anji Reddy Campus, Hyderabad. Join us in creating awareness; through timely diagnosis and treatment of refractive errors in children, we can give them a 'Clear Vision for a Bright Future'. About LVPEI: Established in 1987, L V Prasad Eye Institute (LVPEI), a World Health Organization Collaborating Centre for Prevention of Blindness, is a comprehensive eye health facility. The institute has ten functional arms to its areas of operations: Clinical Services, Education, Research, Vision Rehabilitation, Rural and Community Eye Health, Eye Banking, Advocacy and Policy Planning, Capacity Building, Innovation, and Product Development. The LVPEI Eye Care Network has 280+ centres across India, including Telangana, Andhra Pradesh, Odisha, and Karnataka. The institute's mission is to provide equitable and quality eye care to all sections of society. The LVPEI's five-tier 'Eye Health Pyramid' model, covering all community areas from the villages to the city, provides high quality and comprehensive - prevention, curative, and rehabilitation – eye care to all. It has served over 36.89 million (3 crores 68 lakh people), with more than 50% entirely free of cost, irrespective of the complexity of care needed. Apollo Radiology International, set to transform Radiology Training in India, by standardising it on par with global standards! AI can’t replace radiologists, it might help in identifying the problems easily, reduce the number of mistakes radiologists commit, thus enable radiologists to spend more time on forming an opinion. pollo Radiology International (ARI) takes a monumental step towards transforming the radiology landscape in India with the introduction of groundbreaking initiatives aimed at bridging the gap in training and expertise in this field. ARI aims to bring world class radiology education facilitated by an international faculty to the doorsteps of Indian Radiologists at an affordable cost. Dr Sreenivasa Raju Kalidindi, CEO & MD, Apollo Radiology International, said “Our commitment to advancing radiology training in India is unwavering. We believe these programs will not only elevate the skills of our radiologists but will also have a profound impact on patient care, reducing misdiagnoses, complications, and unnecessary deaths." Radiology, a pivotal medical specialty, has witnessed unprecedented growth globally due to advancements in technology both in the diagnostic and interventional fields. Radiologists in the western world now hold a key position in the patient pathway, both in respect of diagnosis and treatment. Radiologists are often the most important person in a multidisciplinary meeting. A Hospital Watch
Microbioz India, November 2023| 23 However, such changes are yet to come in India. This is largely due to radiologists often lacking specialized training and access to international qualification. In recent years, the rapid growth of radiology in India has been hindered by varied training durations and inconsistent quality across the country. Recognizing this, ARI Academy, a part of the Apollo Group, has emerged as a gamechanger, introducing international standards of education to Indian radiologists. ARI recognizes the disparity in radiology training in India compared to developed countries. Under the umbrella of ARI Academy, a pioneering endeavour by Apollo Radiology International, the focus is on creating learning opportunities at par with Western training schemes. "The Global Radiology Training Program is a transformative initiative designed to enrich the skills and opportunities for radiologists in India and abroad. We are proud to contribute to the global advancement of radiology through this program." said Prof Subhasis Chakraborty, Course Director, Global Radiology Training Program, ARI. Dr Sreenivasa Raju Kalidindi said, lot of diseases are diagnosed today using scanning without the need for surgery or invasive procedures. So radiology has become very important, radiologists play a critical role in patient management. There are high end equipment accessible in India, but the training of the Doctors that read these scans, the radiologists hasn’t changed much, they still do the 3 years PG program like they did in 1960s or 1970s and the training quality is not same across the board. If the doctors knowledge is not upgraded, the quality of diagnosis is also compromised and ultimately patients suffer. We set out to improve the situation in India and help produce more proficient radiologists. Lot of radiologists aspire to get the Fellow of the Royal College of Radiologists’ qualification, the UK Royal college exam, for which they had to wait for several years to attempt the exam, visit UK at least thrice to qualify and was only affordable to a small section of Indian doctors. After enormous effort we could get an examination centre in India for FRCR, which is considered to be a major benchmark in the history of radiology in this country. Now we conduct these exams two or three times a year and several radiologists take those exams. The Indian radiologists didn’t have good success rate in FRCR, so we are running preparatory courses to enhance the success rate. We started a program called the Global Radiology Training Program, which is a two years course, which the radiologists can do while doing MD or DNB PG course, this will support their training and make their competency on par with the Western trained Radiologists. To have specialist radiologists on specific organs of the body, we developed a mini fellowship concept of a week or a month long online coaching, focussing on one area of the body. The first program we are doing is the abdominal mini fellowship happening right now with the support of faculty from Harvard Medical School. AI will not replace radiology but will support it to enhance its role. There are two things we do as radiologists; one is detecting the abnormality and second is interpreting and coming to a clinical conclusion. It’s the second bit that AI can’t replace, it might help us in identifying the problems easily, might reduce the number of mistakes radiologists do. This will aid radiologist to spend more time on forming an opinion. Dr David Roberts, Retired Consultant Radiologist, Wales, UK; said, the problem with Indian radiologists is not the knowledge they have, but the tips and tricks that we could bring to them can improve their performance in the Royal college exam, that’s what we did in the last five years. This the only course in the world which helps afford a level playing field for the Indian candidates. The qualifying rate of Indian students was 30% to 40% in the past, now with this course it’s up to 60%, which is on par with the UK candidates. The fantastic course we are offering at Hyderabad has made a huge difference to Indian Radiology. Some of the key initiatives through which ARI plans to achieve this goal are Fellow of the Royal College of Radiologists Qualification Center in India: ARI Academy, in collaboration with the Royal College of Radiology, London, has established a centre in Hyderabad, allowing hundreds of Indian radiologists to take the renowned Fellow of the Royal College of Radiologists exams locally. This ground-breaking initiative eliminates the need for expensive and time-consuming trips to London, making the qualification more accessible. Global Radiology Training Program: A two-year course, parallel to the MD or DNB postgraduate schemes in India, is bringing global experts from prestigious institutions like Harvard, Oxford, and MD Anderson to teach Indian radiology postgraduate students. This program introduces a thorough core radiology training based on a comprehensive curriculum and enhances their expertise, ensuring they are on par with their Western counterparts. This programme is being led by Prof. Subhasis Chakraborty from Oxford, UK who has the experience of working extensively for the Royal College of Radiologists in UK, is shaping and running their training programmes and examinations. Hospital Watch
Microbioz India, November 2023| 24 Interventional Radiology Training Program: ARI Academy addresses the shortage of interventional radiologists in smaller towns by offering a comprehensive training program. Led by Professor Sanjeeva Kalva, Chief of Interventional Radiology at Harvard Medical School, the program aims to broaden access to interventional radiology and reduce unnecessary surgeries. Abdominal Mini Fellowship: A highly specialized training program focusing on abdominal radiology in partnership with faculty from Harvard Medical School. This initiative brings world-renowned experts to Hyderabad, enabling trainees to gain expertise in a specific area. FRCR 2B Course: ARI Academy proudly hosts India's largest FRCR 2B onsite course, with over 8 successful batches and 350+ participants to date. Guided by esteemed leaders, including a former FRCR exam board chairman and renowned UK faculty, our commitment to excellence in radiology education continues to elevate standards in the field. State-of-the-Art Educational Research Center: A new 18,000 square feet facility has been established at the Apollo Medical College, Hyderabad campus, equipped with teaching rooms, viva rooms, faculty rooms, and a large AI research lab. This centre is set to become a hub for radiology education and research in India. About Apollo Radiology International (ARI) Apollo Radiology International (ARI) provides remote radiology services in the US and across the globe in all major modalities including CT, MRI, PET, Ultrasound, Plain Films/CR, Mammograms and PET-CT studies. ARI is a specialist radiology division of the Apollo Hospitals Group (One of Asia’s Largest Healthcare Group) that has 40 years of legacy in healthcare leadership and excellence. Our experience in teleradiology includes STAT reporting and elective subspecialty reporting of advanced imaging for hospital, mobile and outpatient imaging centers. In addition, ARI offers round the clock full suite of teleradiology services covering Pre-Reads, Prelim - Reads, Final Reads, Vacation Coverage, After Hours, Over Reads & Peer Review. About ARI Academy: ARI Academy is the radiology training vertical of Apollo Radiology International (ARI). ARI’s dedication to empowering the future generation of radiologists sets us apart. Our esteemed ARI Academy offers comprehensive radiology education, catering to both residents and practicing radiologists. As the sole full-fledged radiology academy in India, ARI provides soughtafter FRCR courses, and mini fellowships, and organizes FRCR exams within India, making it more accessible for aspirants outside the UK. Partnered with esteemed organizations like NHS, RCR, BIR, and BAPIO, ARI conducts various courses, exams, and fellowship programs, solidifying our position as a trusted resource for professional development in radiology. ARI’s unique amalgamation of services, state-ofthe-art technology, and comprehensive academy sets us apart from other teleradiology providers in India. With a focus on bridging the healthcare gap between urban and rural areas, leveraging AI for accurate diagnostics, and fostering radiology education, ARI emerges as a beacon of excellence and a catalyst for the future of radiology in India. Our commitment to quality, innovation, and growth makes us the go-to destination for radiologists seeking a rewarding career and a deeper insight into their sub-specialties. Oasis Fertility, Tirupati conducts Baby Shower to felicitate mothers-tobe who conceived through IVF here are millions of fertility challenged couples in India. Though there is a wide array of advanced fertility treatments that can help couples overcome infertility and enable them to have a biological child, many are not aware of such advancements and hence give up hope. Erratic lifestyles, lack of exercise, PCOS, advanced maternal age, etc. affect conception. Taking the help of a fertility specialist at the right time is crucial. Oasis Fertility, Tirupati is one of the best fertility centres in India that offers personalized fertility treatments that are affordable and backed by technology. T Hospital Watch
Microbioz India, November 2023| 25 The centre recently organized an event to felicitate all the mothers-to-be who conceived through IVF treatment. Dr R. Sirisha, Mayor, Tirupati Municipal Corporation, Sandhya Arani, Corporator, Tirupati Municipal Corporation and Dr Jahnavi Esanakula, Consultant Fertility Specialist & Laparoscopic Surgeon, Oasis Fertility, Tirupati graced the occasion. Dr R. Sirisha, Mayor, Tirupati Municipal Corporation; said, the success rate at this branch of Oasis in Tirupati is 70% according to the Doctors here, which is an excellent success rate. As a Gynecologist I am aware that success in infertility treatment is tough, no infertility treatment can give 100% success; maximum success rate is 50%, but this branch of Oasis is ensuring 70% success rate, which means the team here is doing an excellent job and appreciate their effort. Infertility off late is becoming a major concern, it may be male factor or female factor or even unexplained reasons. Such couples suffering from infertility can benefit from infertility centers in Tirupati, earlier such couples had to go to Bangalore, Chennai and other cities. But several infertility centers have been set up in Tirupati, Oasis here is doing excellent work and wish them the best to continue such good work. Speaking on the occasion, Dr Jahnavi Esanakula, Consultant Fertility Specialist & Laparoscopic Surgeon, Oasis Fertility, Tirupati stated, “My heartfelt congratulations to all the mothers-to-be who came out of their fears, inhibitions and took the right step at the right time. We offer highly personalized fertility treatments and follow a holistic approach to help couples attain parenthood. With advanced technologies like PGT (Pre-implantation Genetic Testing), we improve the success rate of IVF and also reduce the risk of miscarriage. Age affects fertility negatively and hence it is important for a couple to seek fertility assistance if they are unable to conceive even after a year”. ABOUT OASIS FERTILITY: Oasis Fertility, a unit of the Sadguru Healthcare Services Pvt. Ltd., has redefined reproductive care in India by bringing in internationally recognized best practices and protocols in Fertility treatments. It offers would-be parents a friendly ‘one-stop’ daycare clinic where consultations, investigations, and treatment are all conducted under one roof. Since its inception in 2009, Oasis has gained an excellent reputation for its high success rates driven by its high-quality services led by a team of experienced infertility specialists with international experience. The chain has expanded to 33+ centres across the states of Andhra Pradesh, Telangana, Tamil Nadu, Karnataka, Jharkhand, Gujarat, Maharashtra, Chhattisgarh and Odisha. Laparoscopy in Gynaecology - a minimally invasive technique ynaecology is an area of medicine that involves treatment of women’s problems, especially those of reproductive organs & related issues. Most common gynaecological problems requiring surgery include infertility (inability to conceive), fibroids in the womb, heavy menstrual bleeding, ovarian cysts, endometriosis, ectopic pregnancy, urinary incontinence etc & the list is exhaustive. A wide variety of treatment options, failing which usually a surgery is offered. Traditionally these surgeries have been performed by giving a cut on the tummy, known as laparotomy. But ever since laparoscopy (keyhole surgery) has been started from early 1900’s a lot of advances happened in minimally invasive surgery fields making it one of most safe & cosmetic way of surgical approach. G Hospital Watch
Microbioz India, November 2023| 26 What is laparoscopy? Laparoscopy is a type of surgery in which the surgeon can visualise the organs inside the tummy after giving 2-4 tiny cuts of 5mm size, distending it with CO2 gas, placing a light source & others instruments to complete the surgery. It’s usually done under general anaesthesia where in the women is put to sleep during the procedure. End of the surgery the gas is let out & the cuts are closed with glue or s=tch. ‘Even if you have scars, you are still beautiful. Scars are tattoos with better stories. What are the surgical fields in which laparoscopy can be done? It can be used to diagnose or treat various gynaecological, surgical, urological etc… conditions. What are the advantages over the conventional open method? Advantages to the women include cosmetic scars, less blood loss, less pain, rapid recovery, shorter hospital stay, better satisfaction & minimal complications like hernia, blood clots in the legs, infections, adhesions etc It also gives the surgeon better opera=ng field & less physical strain in the form of retraction unlike in open surgeries Does laparoscopic surgeries have any disadvantages? In case of unanticipated findings or untoward complications there may be a need of conversion to laparotomy (open surgery), regarding which detailed counselling will be done prior to the surgery. Also, the equipment & the procedure cost is more than the open methods. What complications can happen during/ after laparoscopy? Minor complications like feeling sick, vomiting, infection, bruising at cut site can happen in 1 in 100, but they resolve spontaneously. However rarely certain serious complications like injury to the adjacent organs (intestines, urinary bladder, blood vessel), can happen especially after multiple previous surgeries due to adhesions. Who cannot have laparoscopy? Women who have significant cardiorespiratory problems wherein they cannot tolerate prolonged abdomen distension with gas or prolonged anaesthesia might not be fit enough to go for laparoscopic surgeries, but the decision will be made by the multidisciplinary team. Is there anything better than laparoscopy? ‘Robo=c assisted laparoscopy’ is an advance wherein the surgeon uses a console to perform the procedure, by controlling the robotic arms. The robotic system provides 3D vision, better precision & allows surgeon to perform more complex procedures. Available evidence says that it has lesser complication rate & better recovery than regular laparoscopy or open methods. But it’s very expensive in the current scenario. ‘Laparoscopy is an art. The science of today is the technology of tomorrow. Dr Sri Harika Bonam Consultant Obstetrician & Gyneacologist & Lap Surgeon, Apollo Cradle & Children’s Hospital, Jubilee Hills. LVPEI Inaugurates Cortical/Cerebral Visual Impairment Resource Centre in Hyderabad 1. Dedicated facility for children with Cortical/Cerebral Visual Impairment (CVI). 2. Offers clinical examinations, tailored vision assessments, and specialized CVI interventions. 3. A collaborative initiative between Columbus Global Services Pvt. Ltd. and L V Prasad Eye Institute to empower CVIaffected children and their families. n a monumental stride toward enhancing the lives of children grappling with Cortical/Cerebral Visual Impairment (CVI), the Institute for Vision Rehabilitation at the L V Prasad Eye Institute proudly announces the inauguration of its dedicated ‘Cortical/Cerebral Visual Impairment Resource Centre’ in Hyderabad. I Hospital Watch
Microbioz India, November 2023| 27 This pioneering centre, made possible through the generous support of Columbus Global Services India Pvt. Ltd., stands as a beacon of hope, aiming to alleviate the challenges faced by children and families affected by CVI. CVI is a brain-based visual impairment wherein the eyes may function normally, but the brain’s ability to interpret and make sense of visual information is impaired. About 30–40% of children with visual impairments are affected by CVI, which is a leading cause of paediatric visual impairment worldwide. A staggering 60-70% of these children also struggle with additional disabilities, intensifying the complexity of their lives. The burden of CVI extends far beyond physical limitations, impacting a child’s learning, social interactions, and overall quality of life. “Dr. Beula Christy, Head of the Institute for Vision Rehabilitation at LVPEI, underscores the significance of early intervention and tailored support for individuals with Cortical/Cerebral Visual Impairment (CVI). She highlights how the Cortical/Cerebral Visual Impairment Resource Centre, with its comprehensive and individualized approach, addresses the multifaceted challenges faced by these children.” This groundbreaking facility offers various services, including clinical examinations, tailored vision assessments, and specialized interventions such as vision therapy, visual skills training, speech therapy, and counselling for children and their families. Additionally, the centre provides home environment modifications, engaging group activities, parental support groups, and independent living skills training, all aimed at enhancing the quality of life for these remarkable children. Dr Prashant Garg, Executive Chair of LVPEI, emphasized the profound impact of this initiative, stating, “Our mission is to empower the children with CVI to navigate the world with confidence and independence. We are enthusiastic about the positive change this initiative will bring to their lives, and we extend our heartfelt thanks to Columbus Global Services Pvt. Ltd. for their generous support.” “We are proud to support the Cortical/Cerebral Visual Impairment Resource Centre at the L V Prasad Eye Institute. We believe in the power of innovation and compassion to transform the lives of children and families affected by CVI. Together, we can create a brighter, more inclusive future,” said Mr Kapil Mishra, Managing Director, Columbus Global Services India Pvt. Ltd. The Cortical/Cerebral Visual Impairment Resource Centre is more than a facility; it is a place of hope, compassion, and innovation. Through the unwavering support of Columbus Global, this initiative is poised to make a substantial difference in the lives of children and families affected with CVI. About LVPEI: Established in 1987, L V Prasad Eye Institute (LVPEI), a World Health Organization Collaborating Centre for Prevention of Blindness, is a comprehensive eye health facility. The Institute has ten functional arms to its areas of operations: Clinical Services, Education, Research, Vision Rehabilitation, Rural and Community Eye Health, Eye Banking, Advocacy and Policy Planning, Capacity Building, Innovation, and Product Development. The LVPEI Eye Care Network has 280+ Centres spread across Telangana, Andhra Pradesh, Odisha, and Karnataka in India. The institute’s mission is to provide equitable and quality eye care to all sections of society. The LVPEI’s five-tier ‘Eye Health Pyramid’ model, covering all areas of the community right from the villages to the city, provides high quality and comprehensive - prevention, curative, and rehabilitation – eye care to all. It has served over 36.89 million (3 crores 68 lakh people), with more than 50% entirely free of cost, irrespective of the complexity of care needed. Hospital Watch
Microbioz India, November 2023| 28 MTaI Bats for Fans Wellbeing: 'No Boundaries’ for Safety in Cricket! n a path-breaking move to prioritize spectator well-being at cricket matches, the Medical Technology Association of India (MTaI), which represents leading research-based medical technology companies with a large footprint in manufacturing and training in India, recently wrote a persuasive letter to both the International Cricket Council (ICC) and the Bureau of Cricket Council of India (BCCI) advocating for the integration of lifesaving medical devices near spectators as a safety measure. A report by Harvard Business School has indicated that the adrenaline rush, stress levels, and emotional fluctuations experienced by spectators at live sports matches can significantly increase the risk of cardiovascular events, brain strokes, etc. In their findings, they underscore the importance of timely access to life-saving medical interventions, such as defibrillators and ECG monitoring, as critical components of spectator safety protocols. The proposed integration includes advanced medical monitoring systems, emergency response equipment, and other cutting-edge technologies that can significantly enhance the ability to respond promptly to any health-related incidents in the crowd. Mr. Pavan Choudary, Chairman, Medical Technology Association of India said, “In the spirit of the game, we believe that safety should know no boundaries. Our representation to the ICC and BCCI underscores the importance of integrating medical technology near spectators, ensuring a healthier and more secure cricketing experience.” "Our vision is to make cricket matches (or any other sporting event), not just a spectacle but a health-conscious, fan-friendly experience. We propose that the cricketing landscape be made safe with the integration of state-of-the-art medical devices strategically placed within the spectator areas, creating a safety net that aligns seamlessly with the thrill of the game", added Mr. Choudary. Adding to Choudary's views, Dr. O. P. Yadava, CEO & Chief Cardiac Surgeon, National Heart Institute & Director, All India Heart Foundation said, "The escalating prevalence of cardiac arrests among India's young population necessitates the integration of life-saving medical devices near spectators during live sporting events. Timely availability of these devices is a critical safety measure, potentially turning a moment of crisis into an opportunity to save lives." Speaking on the issue of spectator safety, Dr. Ratna Devi, Director, Patient Academy for Innovation and Research & Chairwoman, ISPOR Patient Council stated, “I believe that the integration of lifesaving medical devices near spectators would be a critical step towards ensuring swift and effective response in the face of potential health emergencies. Just as we prioritize patient safety within the confines of a hospital, extending this commitment to public spaces, like cricket stadiums, large events and other venues will be a logical and necessary progression. This move could establish a new standard for public health at sporting events, setting an example for global best practices in ensuring the safety and well-being of diverse audiences." MTaI's letter to the cricket councils emphasizes the collaboration between the medical technology industry and cricketing bodies to establish a new standard for fan safety. MTaI also believes that this initiative will not only set a precedent in cricket but also inspire similar measures across other sporting events globally. About Medical Technology Association of India (MTaI): Medical Technology Association of India (MTaI– pronounced as Em-tai) is a not-for-profit organization duly registered under sub-section (2) of section 7 of the Companies Act, 2013 and Rule 8 of the Companies (Incorporation) Rules, 2014. MTaI is an association of research-based medical technology companies that have made remarkable investments in Manufacturing, R&D, and Health Care Workers Training in India. MTaI represents a wide spectrum of the medical device industry with global experience in innovation and manufacturing. All the time stressing the three hallmarks of healthcare - Quality, Consistency, and Patient Safety, MTaI wants to be a responsible voice in the industry. I Hospital Business
Microbioz India, November 2023| 29 The association is committed to improving access to affordable and quality healthcare for patients. MTaI looks to partner with the Government of India in setting a roadmap for the growth of the medical devices sector by bringing in even bigger investments in this sector, through 'Make in India’ and through technology upgradation and dissemination in the provider space. American Oncology Institute (AOI) Hisar Performs its First Hybrid Interstitial Brachytherapy Procedure merican Oncology Institute, Hisar, continues its legacy of groundbreaking medical achievements with the successful completion of its first Hybrid Interstitial Brachytherapy procedure in combination with Varian's Linac IGRT. The patient, a 50-year-old female diagnosed with Stage 3 Cervix Cancer, was the recipient of this cutting-edge procedure. Cervix cancer, while challenging, is highly treatable, and this advanced technology further elevates the odds of a successful recovery. According to data shared by the Union health ministry in Lok Sabha recently, the collective estimated incidence of cancer cases, in both men and women, in Haryana has gone up by 4.95% between 2020 and 2022. The importance of screening for cervical cancer cannot be overemphasized, because diagnosis at the earliest stage of disease is the key to achieving a complete cure without recurrence. Dr Sumeet Aggarwal, Radiation Oncologist, AOI Hisar, explained, "Hybrid Interstitial Brachytherapy is a significant advancement in the field of radiation therapy. It offers a powerful tool allowing for highly targeted and localized treatment. Combining Hybrid Interstitial Brachytherapy with Linac IGRT creates a comprehensive treatment approach. This combination leverages the precision of IGRT to ensure accurate positioning and then delivers interstitial brachytherapy directly to the tumor site, optimizing the therapeutic impact while minimizing damage to surrounding healthy tissues. At AOI Hisar, we use it for complex or challenging cases, such as advanced stage cancer, where precise targeting is critical for treatment success and minimizing side effects. This groundbreaking procedure empowers us to provide tailored treatments for each patient, taking us one step closer to a world without cancer." Dr Amit Dhawan, RCOO, AOI Hisar said, “At AOI, we are committed to pushing the boundaries of medical excellence. The successful Hybrid Interstitial Brachytherapy procedure using Varian's Linac IGRT is a testament to our dedication to providing our patients with the best available resources. We invest in state-of-the-art technology because we understand that innovation is the cornerstone of modern healthcare. It enables us to offer more precise, effective, and patientfriendly treatments, ensuring that our patients receive the highest standard of care. American Oncology Institute, Hisar, takes immense pride in this achievement, recognizing it as a giant leap towards enhancing the quality of cancer care.” American Oncology Institute (AOI) at Sarvodaya Multi Speciality Hospital in Hisar is one of the best cancer hospitals in Haryana, offering a wide range of cancer treatment services in the region. As a proud member of the elite global network of the International Tumor Board, AOI in Hisar collaborates closely with leading medical professionals worldwide, ensuring that our patients receive the most advanced and informed treatment options available at the best hospital in Haryana. AOI Hisar specializes in a range of dedicated services, making it the best hospital in Haryana. Committed to excellence, AOI combines clinical expertise, state-of-the-art technology, and compassionate care to deliver the highest standard of cancer treatment in the region. A Hospital Business
Microbioz India, November 2023| 30 Drools Pet Food unveils ambitious initiatives to elevate pet healthcare services in India 1. Launch the ‘Vet Thrive’, a vet clinic upgradation scheme, with a substantial investment of INR 25 crore to enhance veterinary clinics nationwide 2. Expands into the Small Animal Pharmaceutical business with the introduction of 'Drools Veterinary Health’ rools Pet Food Pvt. Ltd., India's leading pet food brand, has announced two transformative initiatives that are poised to redefine the landscape of pet healthcare services and veterinary practices across the nation. Drools has introduced ‘Drools Vet Thrive’, a vet clinic upgradation scheme, a visionary initiative designed to elevate pet healthcare services nationwide. With a substantial investment of INR 25 crores, this pioneering initiative is set to reshape the landscape of pet healthcare services and veterinary practices across India, marking a significant milestone in the commitment to animal welfare and well-being. This comprehensive scheme aims to elevate pet healthcare services by deploying state-of-the-art equipment, including advanced diagnostic instruments and surgical gear, across veterinary clinics in India. It also equips veterinarians with cutting-edge tools, ensuring the delivery of superior care to pets. In another strategic diversification, Drools is venturing into the Small Animal Pharmaceutical arena with the launch of 'Drools Veterinary Health.' The launch was facilitated by Malika Arora at the Federation of Asian Small Animal Veterinary Association (FASAVA) Congress 2023, one of the biggest Veterinary events held at Hotel Westin Mumbai. Dr. Shashank Sinha, CEO and Veterinarian at Drools Pet Food Pvt. Ltd., “At Drools, we are deeply committed to the holistic well-being of pets. Our 'Drools Vet Clinic Upgradation Scheme' and the launch of 'Drools Veterinary Health' highlight our unwavering dedication to enhancing pet healthcare and providing pets with the best possible care. By extending these enhancements to veterinary clinics nationwide, we are ensuring that pet parents across the country can access top-tier pet healthcare services. The introduction of 'Drools Veterinary Health’ underscores Drools' dedication to comprehensive pet care and underscores our vision to become a holistic partner within the pet healthcare ecosystem. Both of our pioneering initiatives are designed to ensure that our furry companions receive the care, attention, and love they truly deserve.” President of Pet Practitioners Association of Mumbai (PPAM), Dr Dhananjay Bapat, said, “Drools is spearheading the liaison of India's pet care and vet services with the international veterinary community. This is a crucial step in India's journey to achieve global standards in pet care. By collaborating with international organizations such as FASAVA and WSAVA, Drools is not only providing Indian veterinarians with access to the latest global best practices but also enabling them to learn from and share knowledge with their international counterparts.” Applauding this initiative, Dr. S Yathiraj, President, Pet Practitioners Association of Karnataka (PPAK) and former Dean of Veterinary College, KVAFSU, Bangalore, states, “The need to improve veterinary services in India is critical, and Drools is playing a vital role in making this happen. The company's initiatives are helping to address and improve access to care for animals and raise awareness about the importance of veterinary care. This is having a positive impact on pet welfare, public health, and the economy. I commend Drools for its commitment to improving veterinary services in India." Drools has earned a reputation for delivering highquality, balanced, and nutritious pet food, consistently setting industry standards in pet care and nutrition. As a brand synonymous with quality, Drools is committed to fostering healthier, happier lives for pets and their owners. D Hospital Business
Microbioz India, November 2023| 31 About Drools: Drools, India’s only MNC pet food company was established in 2010 by Fahim Sultan and is the flagship brand of DROOLS PET FOOD PRIVATE LIMITED. Set up in 2009 to focus on nutrition, health and welfare of pets, Drools was born to bridge a gap and ensure that all pets received the right kind of clean ingredients with wholesome balanced nutrition. The production of pet food for dogs and cats began in 2010 and Drools today, is one of the fastest growing pet food brands in South Asia with large product ranges developed with international quality standards. Export led growth has been a dominant paradigm for Drools and the company has seen exponential growth in the last decade. The first consignment of Drools Daily Nutrition Dry Dog Food and Dry Cat Food was exported to Sri Lanka in the year 2012 and then to Kathmandu, Nepal within the same year. At present Drools exports to 22+ countries and some select countries in the African continents. What started as a bare minimum product line has now expanded to Premium Dog Food, Economy Brand Packs, Treats, Supplements in addition to Dry Dog and Cat Food. Apollo Hospitals Celebrates 25 Years of India's First Liver Transplant Program 1. Apollo Hospitals pioneered India's first successful liver transplant in 1998. 2. The first liver transplant patient, who was 20 months old at the time, is now a doctor. 3. Apollo Hospitals has played a leading role in positioning India as a global leader in organ transplantation. 4. Over the past 25 years, the Apollo Institutes of Transplantation have performed over 4300 liver transplants for patients from more than 50 countries including 515 in children. pollo, the world’s largest integrated healthcare provider, has been at the forefront of patient care in India and has led the organ transplant revolution in healthcare. Today the Apollo Hospitals Group celebrated the completion of 25 years of paediatric liver transplant program in India. The Apollo Transplant program is one of the world’s largest and most comprehensive transplant programs performing more than 1600 solid organ transplants a year. The program offers a host of state-of-the-art services which include Management of Liver Disease, Management of Kidney Disease, Liver and Kidney Transplantation, Heart and Lung Transplantation, Intestinal, Pancreas and GI Transplant Surgeries and Pediatric Transplant Services. With 90% success rates, The Apollo Liver Transplant program is a beacon of quality and hope for patients from across the world. Dr. Preetha Reddy, Vice Chairperson, Apollo Hospitals Group said “Liver disease remains a significant concern within the country, resulting in the annual loss of approximately 200,000 lives. Despite approximately 1,800 liver transplants conducted each year, the demand for this procedure reaches as high as 20,000 individuals at any given time. While India has made substantial progress since the inception of these operations, a considerable gap remains unaddressed. At Apollo, our dedication lies in ensuring that no individual succumbs due to a lack of access to transplantation. Our focus involves establishing top-tier transplant centres, led by esteemed clinicians. We are committed to extending our expertise to individuals worldwide seeking liver transplant services.” Marking the occasion, Apollo Hospitals’ Group Medical Director and Senior Pediatric Gastroenterologist, Dr. Anupam Sibal said, “Today is a significant milestone for Indian medical advancements. The liver transplant program at Apollo Institutes commenced 25 years ago, marking a pivotal moment in India's medical landscape. This ground breaking initiative, coupled with the resilience shown by patients like Sanjay, has led the Apollo Institutes of Transplant to successfully carry out over 4300 liver transplants, including 515 procedures in children. A Hospital Business
Microbioz India, November 2023| 32 I distinctly remember the day I first saw Sanjay, the hours spent in the ICU and today 25 years on, Dr Sanjay will soon be married. As his doctor, I cannot express the happiness and satisfaction I am feeling in words. Today we are able to perform the most challenging transplants including ABO incompatible and combined liver-kidney transplants. We are also operating on babies as small as 4 kgs.” Highlighting the expertise developed at Apollo, Dr. Neerav Goyal, Sr. Consultant, Liver Transplants said, "Apollo's liver transplant program has an exceptional success rate of 90%, a testament to our unyielding dedication to unparalleled patient care and clinical outcomes. This achievement not only represents our commitment to excellence but also serves as a beacon of hope for those confronting liver failure. We intend to further develop our program to help an even larger section of the population in the future. The success of our program reflects the tireless efforts, skill, and advancements in the field of liver transplants, solidifying our position as a leading institution offering renewed chances for a healthier life”. Mr. Shivakumar Pattabhiraman, Managing Director of the Indraprastha Apollo Hospitals, New Delhi, said, India's prominence in organ transplantation is on the rise. With a rich legacy spanning 25 years, we at Apollo celebrate a landmark achievement in liver transplantation, solidifying its position as a pioneering force in India's medical domain. The institution stands as a beacon of exceptional care and ground breaking advancements, setting global standards in liver transplants. Our unwavering commitment to advancing liver transplantation and relentless pursuit of pushing the boundaries of medical science underscores a pledge to deliver the best outcomes for our patients.” Noted Film Actress Ms Dimple Kapadia, who graced the function said, “In Dil Chahta Hai, my character Tara Jaiswal died because of a silent killer. Liver Cirrhosis. As we go about our daily lives, we often neglect the importance of our liver, this unsung hero of our bodies. Our liver is a remarkable organ, tirelessly working to cleanse your blood, store energy, and produce essential proteins. It is the silent guardian that protects us from harmful toxins and keeps us healthy. But just like any other organ, it can be damaged, and when it is, the consequences can be devastating. Liver cirrhosis leads to liver failure which took Tara’s life. At that point in time, Liver Transplantation wasn’t well established in India. Today, Liver transplantation is a life saving therapy saving lives every day. Liver Transplantation has given a new lease of life to Sanjay, the first child in India to receive a liver transplant, Prisha the 500th child transplanted at Apollo and hundreds of children and adults not just from India but from 50 countries across the world. I would like to congratulate the Apollo Team and wish them the very best in their commitment to save lives”. Additionally, Dr Sanjay Kandasamy said, “I am the first beneficiary of the Apollo Liver transplant program. My second chance at life and the excellent quality of life are a testament to the extraordinary expertise and precision of the medical marvels at Apollo. The success of the liver transplantation reaffirms Apollo's commitment to pioneering advancements, unrivalled medical acumen, and unwavering dedication to patient well-being. Today, I stand as an example to the triumph of medical ingenuity.” About Indraprastha Apollo Hospitals: Indraprastha Apollo Hospitals, India’s first JCI accredited hospital, is a joint venture between the Government of Delhi and Apollo Hospitals Enterprise Limited. Commissioned in July 1996, it is the third super-specialty tertiary care hospital set up by the Apollo Hospitals Group. Spread over 15 acres, it houses 57 specialties with more than 300 specialists and more than 700 operational beds, 19 operation theatres, 138 ICU beds, round-the-clock pharmacy, NABL accredited laboratories, 24-hour emergency services and an active air ambulance service. Apollo Hospitals Delhi has the leading programme in kidney and liver transplant in the country. The first successful paediatrics and adult liver transplants in India were performed at Indraprastha Apollo Hospitals. The hospital is at the forefront of medical technology and expertise. It provides a complete range of latest diagnostic, medical and surgical facilities for the care of its patients. The Hospital has introduced the most sophisticated imaging technology to India with the introduction of 64 slice CT and 3 Tesla MRI, Novalis Tx and the integrated PET Suite. Indraprastha Apollo has also pioneered the concept of preventive health check programmes and has created a satisfied customer base over decades. The Hospital has been consistently ranked amongst the best 10 hospitals in India by The Week survey for the past few years. Hospital Business
Microbioz India, November 2023| 33 Lab-on-a-Chip Genetic Test Device Identifies Viruses in Three Minutes Story Source/Credit: University of Bath virus diagnosis device that gives lab-quality results within just three minutes has been invented by engineers at the University of Bath. The prototype LoCKAmp device uses innovative lab-on-a-chip technology and has been proven to provide rapid and low-cost detection of COVID from nasal swabs. The research team, based at the University of Bath, says the technology could easily be adapted to detect other pathogens such as bacteria—or even conditions like cancer. The device works by rapidly releasing and amplifying genetic material from a nasal swab sample by carrying out a chemical reaction to produce a result, which can be viewed on a smartphone app. Unlike lateral flow assay tests, commonplace during the pandemic, the LoCKAmp employs the same “gold standard” genetic-based testing techniques previously reserved for lab-based PCR (polymerase chain reaction) tests, thus enabling rapid testing at laboratory-scale standard. Made with off-the-shelf components and factorymanufactured printed circuit boards, the prototype device could be made on a mass scale quickly and at low cost, presenting care providers and public health bodies around the world with an effective new tool in virus detection. The research team says a commercial partner with the relevant design and manufacturing expertise could quickly redesigned the LoCKAmp into a small, portable device – with great potential for use in remote healthcare settings. The research team is already engaging with academic and commercial partners, and would welcome further approaches, as it seeks to bring LoCKAmp into production. The device and how it works is detailed in the research paper LoCKAmp: lab-on-PCB technology for <3 minute virus genetic detection, published in the journal Lab on a Chip. Despina Moschou, PhD, from Bath’s Centre for Bioengineering & Biomedical Technologies (CBio), led the research “We started researching and developing LoCKAmp during the second wave of Covid in the UK,” says Moschou. “We were confident we could create a portable, low-cost device that could carry out genetic identification of the virus, like a PCR test, within 10 minutes. We have done that, but found it can actually work within just three minutes. “This is an amazing display of the possibilities of lab-on-a-chip technology, and given the low cost and adaptability of the technology to detect a range of conditions, a potentially highly valuable and unique tool for a range of healthcare settings.” By using readily available printed circuit board technology and the associated mass manufacturing infrastructure, the team says the device can be produced quickly and cheaply at scale. LoCKAmp comprises a portable testing unit, and disposable cartridges, which are used for each test. Further reading: Lab-on-a-Chip Technology Screens Live Tumor A Product Launches
Microbioz India, November 2023| 34 How LoCKAmp works LoCKAmp harnesses a process known as RTLAMP (reverse transcription loop-mediated isothermal amplification) to multiply specific sequences of RNA, meaning it can quickly detect the particular virus it is looking for. The team says LAMP detection is preferable to PCR testing as it has higher sensitivity, is faster, and more specific. Crucially, processing takes place at a single stable temperature, instead of needing the three thermal cycles a PCR test requires. This means the device can be made easier at a portable size, and with lower power consumption. A further benefit of the design is that no pre-processing of the nasal swab samples is required. Once a nasal swab sample is added to the device, the LoCKAmp pumps the liquid through tiny transparent ‘microfluidic’ channels layered onto the circuit board, above copper heaters just 0.017mm thick. These heat the sample, releasing the RNA genetic material from the virus. This is then further heated and treated with RT-LAMP chemicals to encourage multiplication. If the specific virus RNA is present in the amplified sample, it fluoresces under light – this signal is then used to denote a positive test. LoCKAmp has been developed by a team led at the University of Bath, including staff from its departments of Chemical Engineering, Chemistry and Life Sciences, as well as colleagues from the James Watt School of Engineering at the University of Glasgow and the John Innes Centre. The device was tested with COVID patient swabs collected by Bath’s Royal United Hospital Trusts, with which the University has a longstanding research partnership, during the third wave of the pandemic. Despite the cessation of the pandemic, particularly in the public consciousness and legislative agenda, development continued, given the adaptability and potential of the device. Scope to Track Outbreaks via Wastewater As well as proving the system’s capability in analyzing nasal swab samples, the LoCKAmp could also be used to carry out anonymized communitylevel monitoring and detection of viruses like COVID, by testing wastewater. This alternative use, which does require some preprocessing of wastewater samples, was arrived upon as the team took advantage of expertise in wastewater-based epidemiology within Bath’s Water Innovation Research Centre. Using LoCKAmp to carry out ongoing, real-time analysis of wastewater could allow public health bodies to quickly detect the spread of viruses like COVID, or other infectious diseases. Doing this via wastewater can give a broader community-wide view, rather than relying on individuals to regularly test for a condition. “With LoCKAmp technology providing both low cost and real-time genetic target identification and quantification, we’re getting ever closer to real-time pathogen tracking,” says Professor Barbara Kasprzyk-Hordern, from Bath’s Department of Chemistry, an expert in environmental epidemiology who contributed to the research. “This opens exciting opportunities enabling the establishment of early warning systems utilizing wastewater for pathogen surveillance in communities.” Noninvasive H. Pylori Diagnostic Solutions by Meridian Bioscience Story Source/Credit: Meridian Bioscience earn about dependable noninvasive H. pylori diagnostic testing solutions, like the BreathID® Smart urea breath test platform. Deliver fast, accurate H. pylori test results with this trusted, patient-friendly platform that combines market-leading diagnostic accuracy with efficient automation in a compact footprint. Our products are designed to fit your unique needs so you can focus on what you do best — providing quality testing to physicians and patients. Working together we can provide solutions to meet your H. pylori testing needs. From low-volume testing to high-volume automation, physician offices to health systems, Meridian is here to help. Whether for initial active infection detection or confirmation of eradication, Meridian is your trusted partner in gastrointestinal diagnostics and has been a leader in H. pylori testing for over 20 years. L Product Launches
Microbioz India, November 2023| 35 Researchers Develop MetalEnhanced Fluorescence Probes for Influenza Detection Story Source/Credit: Department of Chemistry at the Gwangju Institute of Science and Technology ecurring influenza epidemics, such as the one during World War I, the Middle East respiratory syndrome coronavirus (MERSCoV) outbreak in the 2010s, and the COVID-19 pandemic in recent years have made it evident that contagious viral respiratory diseases often make an appearance in the timeline of human history. Denser populations, close contact during transportation, and improvements in connectivity have significantly increased the rate of spread of such viral infections. To minimize viral transmission and mass infection, rapid diagnostic tests that can detect and identify viruses are essential for effective isolation and treatment of infected patients. In recent years, fluorescence-based lateral flow immunoassay (LFI) has gained popularity as a diagnostic tool for viral detection. It is a rapid virus detection platform which uses molecules that glow under special lighting conditions in the presence of a viral load. However, the performance of this detection platform is limited due to several issues related to detection sensitivity. In a recent study, a team of researchers led by Professor Min-Gon Kim from the Department of Chemistry at the Gwangju Institute of Science and Technology have now demonstrated that these fluorescence-based LFIs, when enhanced by gold nanorod (GNR)-based probes, could accurately and rapidly detect an influenza virus protein, without the need for complex diagnostic laboratory equipment. Their work was made available online on Aug. 18, 2023, and published in Volume 17, Issue 17 of ACS Nano. To this end, the team developed Cy5- mSiO2@GNR probes with core–shell nanostructures for the LFI platform. These probes consist of a GNR core, a mesoporous silica shell (mSiO2), and the fluorescent molecule cyanine 5 (Cy5). This new biosensing system bypasses common problems associated with fluorescencebased LFI, such as photobleaching of fluorophores and low quantum yields, by leveraging metalenhanced fluorescence (MEF). Further reading: Improving Diagnostic Accuracy of Influenza Via At-Home Testing “The platform developed by us uses a phenomenon where light-matter interactions in the vicinity of metal nanoparticles give rise to a plasmonic effect, producing a strong fluorescence. The key factors that dictate this effect are the distance and spectral overlap of the metal and fluorophore in the MEF system,” says Kim. R Product Launches
Microbioz India, November 2023| 36 The team then subjected the Cy5-mSiO2@GNR probes to a series of theoretical and experimental tests to investigate the dependence of fluorescence behavior on the distance between the GNR and Cy5 by adjusting the thickness of the mSiO2 shell. They found that a thickness of 10.3 nm was optimal for the shell and accordingly set the morphology condition of the MEF system to achieve an enhanced fluorescence effect. Furthermore, they demonstrated the applicability of optimized MEF probes by incorporating it onto a LFI platform for the detection of influenza A virus (IAV). Due to the improved fluorescence, the MEF-LFI system was able to detect IAV even at very low concentrations of 1.85 pfu mL-1 within 20 minutes. It also showed high specificity towards IAV even in the presence of other viruses, such as MERS-CoV and the COVID-19 virus. Furthermore, this biosensing system was able to identify IAV from clinical patient samples with a remarkable accuracy of more than 99%. “The findings of this research can not only transform rapid testing in healthcare, but its scope can be also extended to other forms of biomolecule diagnostics, with the ultimate goal of improving people’s quality of life,” says Kim. Featured image: The new metal-enhanced fluorescence-based LFI platform can detect influenza A virus with great accuracy and specificity, in under 20 minutes, which is highly promising for biomolecule detection. Photo: Gwangju Institute of Science and Technology (GIST) Lucid Diagnostics Launches Next-Gen Esophageal DNA Test Story Source/Credit: Lucid Diagnostics ucid Diagnostics, a commercial-stage, cancer prevention medical diagnostics company, announced that its CAP-accredited, CLIAcertified laboratory, LucidDx Labs, has launched the next generation of the EsoGuard Esophageal DNA test for the detection of esophageal precancer, having demonstrated enhanced assay performance and lower costs in extensive validation studies. All commercial and research samples received by the laboratory will now be processed using the EsoGuard 2.0 assay. “The launch of EsoGuard 2.0 is a seminal milestone for our company and the culmination of over a year of meticulous R&D work by our Chief Scientific Officer, Suman Verma, MD, PhD, and her dedicated and talented team,” says Lishan Aklog, MD, Lucid’s Chairman & Chief Executive Officer. “EsoGuard had previously demonstrated unprecedented cancer and precancer detection results, including detecting 100 percent of esophageal cancers and over 80 percent of precancers in a recent study from the National Cancer Institute-funded BETRNet consortium. EsoGuard 2.0 improves upon EsoGuard 1.0’s already outstanding performance in multiple respects, including by enhancing DNA yield, streamlining down-stream processes that incorporate advanced molecular techniques and more efficient bioinformatics, and enabling higherthroughput testing. These improvements also lower the per-sample costs of the assay, which we expect to decrease even further in the coming months when we upgrade our NGS-sequencing platform to a higher-throughput model to accommodate increased EsoGuard testing volume. We appreciate the critical input of Sandy Markowitz, M.D., Ph.D., and his colleagues at Case Western Reserve University, the inventors of EsoGuard, in helping us reach this milestone.” The results of the analytical validation studies of the EsoGuard assay, culminating in EsoGuard 2.0, have been accepted for presentation at the upcoming Association of Molecular Pathology Annual Meeting (AMP 2023). The EsoGuard assay involves first extracting DNA from esophageal cells collected by the EsoCheck Cell Collection Device. The DNA then undergoes bisulfite conversion, which tags sites which are not methylated. Two genes, VIM and CCNA1, with 31 methylation sites that correlate with esophageal precancer and cancer, are amplified using polymerase chain reaction (“PCR”) techniques and then sequenced using next-generation sequencing (“NGS”) techniques. Advanced bioinformatics software analyzes the DNA sequence data and determines the proportion of the 31 target sites which are methylated, returning a positive or negative EsoGuard result. L Product Launches
Microbioz India, November 2023| 37 The original version of the assay used a singleplex technique, which required the DNA to be split and separately processed for each gene. EsoGuard 2.0 uses multiplexing which allows both genes to be interrogated on a single DNA sample. This breakthrough allows the laboratory to run the assay three times and call positive and negative results by consensus, blunting stochastic noise for low positive samples near the cutoff. The next-generation assay underwent rigorous analytical and clinical validation studies, including head-to-head comparisons of multiplexed triplicate consensus versus singleplex techniques, consistent with CLIA standards, the company says. Clinical validation analysis included samples from the ESOGUARD-BE-1 study and demonstrated improved sensitivity and specificity. Quest Launches Mobile Phlebotomy Service for At-Home Specimen Collection Story Source/Credit: Quest Diagnostics uest Diagnostics announced the launch of Quest Mobile, a service designed to make it easier and more convenient for patients to have a specimen collected for lab testing nationwide. Patients can request an appointment for at-home specimen collection with a trained Quest Mobile phlebotomist for a broad range of laboratory tests in the comfort of their homes. “People increasingly value choice and convenience in healthcare, including lab testing. Quest Mobile provides an outstanding option for individuals to access critical testing services on their own terms, from a provider they trust for quality and service,” says Patrick Plewman, senior VP, diagnostic services, Quest Diagnostics. “Quest Mobile also reflects Quest’s strategy to develop innovative solutions, based on our expertise and scale, to serve the evolving needs of customers, including greater interest in at-home care.” Quest Mobile service will be available in 44 states. Patients whose physicians or health providers order laboratory testing from Quest, including consumers requesting consumer-initiated testing services from questhealth.com, can now schedule a mobile phlebotomy appointment for a fee at Appointment.QuestDiagnostics.com. Quest Mobile does not bill to a patient’s health insurance, and patients will pay a $55 mobile collection fee at time of scheduling. The company is currently working with healthcare providers, health systems, and health plans to arrange commercial pricing to eliminate out-of-pocket cost for patients. Q Product Launches
Microbioz India, November 2023| 38 Further reading: Quest Launches Prostate Cancer Test to Improve Diagnosis and Grading Once scheduled, a trained Quest Mobile specialist will complete the patient’s blood draw or other specimen collection at the individual’s location and bring their specimen to a Quest Diagnostics patient service center – with no handoffs in specimen transport or processing to a third-party provider. Over 800 Quest tests are available for mobile collection with a physician’s order, from routine cholesterol and diabetes screenings to prenatal carrier screenings and evaluations for Lyme disease, including other commonly ordered tests. Quest’s new service complements the company’s current service options, which include online appointment scheduling and walk-in visits at one of Quest’s 2,100 patient service centers as well as inoffice phlebotomy at some health provider sites. Test ordering and reporting remains unchanged. “Issues like access and convenience shouldn’t prevent patients from receiving needed lab services,” says Subu Ramachandran, VP and general manager of Quest Diagnostics’ ExamOne unit, which initially built the mobile phlebotomy network to support in-home health examinations for life insurance applicants. “Quest Mobile provides patients and physicians a seamless connection to Quest Diagnostic’s laboratory testing, allowing us to work together for a healthier world – one life at a time.” Roche’s Neurofilament Light Chain Test Gets Breakthrough Device Designation Story source/Credit: Roche oche’s Elecsys Neurofilament Light Chain (NfL) test for multiple sclerosis (MS) received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). The Elecsys NfL test is intended to be used as an aid in detection of disease activity in adults (18-55 years old) with relapsing-remitting multiple sclerosis (RRMS) or secondary progressive multiple sclerosis (SPMS), providing critical insights for disease management. “Around 2.8 million people are estimated to live with multiple sclerosis (1). After diagnosis, many face challenges with managing their disease due to significant gaps in access to testing. This can lead to missed opportunities to detect disease progression in support of treatment optimization,” says Matt Sause, CEO of Roche Diagnostics. R Product Launches
Microbioz India, November 2023| 39 “We are excited about the potential Elecsys NfL has to improve outcomes for MS patients by offering a minimally invasive blood draw that can deliver rapid results.” Further reading: Roche Expands HPV Testing for Cobas 5800 Molecular System Approximately 85% of MS cases are RRMS patients.(2) The majority of people diagnosed with RRMS eventually transition to SPMS, in which neurologic function worsens over time and disability increases. For patients with RRMS and SPMS, detection of disease activity is critically important in enabling them and their physicians to make the best possible decisions for the management of the disease. Although the current spotlight for NfL’s intended use is multiple sclerosis, increases in NfL concentrations have been reported in individuals with other neurodegenerative diseases, such as Alzheimer’s and Huntington’s diseases and in indications beyond neurology. Elecsys NfL has the potential to help laboratories to scale MS testing on widely available, fully automated and standardized Roche cobas instruments with the confidence of in-vitro diagnostics quality, in a timely manner, according to Roche. In July 2022, the FDA also granted Breakthrough Device Designation to Roche’s Elecsys Amyloid Plasma Panel, a new solution to enable Alzheimer’s disease to be detected earlier. Elecsys NfL receiving this designation is an important step as the organization strengthens its diagnostics neurology portfolio to meet growing societal needs. About Elecsys NfL Neurofilament Light Chain (NfL) is an abundant protein exclusively present in neurons and a sensitive indicator of neuroaxonal damage. Under normal conditions, NfL is released at low level from axons; however, this rate increases with age and following neuroaxonal damage. Therefore, abnormal, elevated levels of NfL can be detected in cerebrospinal fluid and blood in various acute and chronic neurological disorders. Although the current spotlight for NfL’s intended use is multiple sclerosis, increases in NfL concentrations have been reported in individuals with traumatic brain injury, amyotrophic lateral sclerosis, frontotemporal dementia, Alzheimer’s disease, Huntington’s disease and other neurodegenerative diseases, (3) but also in other indications beyond neurology. Featured image: Roche’s Elecsys Neurofilament Light Chain (NfL) test can be run on the cobas e 801 instrument. Photo: Roche References 1. Walton C, King R, Rechtman L, et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult Scler. 2020 Dec; 26 (14):1816-1821 2. MS Society [Internet; cited 2023, Oct 25] 3. Mayo Clinic. [Internet; cited 2023, Oct 25] Invitae Launches Enhanced Chemistry of MRD Test Story source/Credit: Invitae nvitae, a medical genetics company, announced enhanced chemistry of its Invitae Personalized Cancer Monitoring platform that helps detect circulating tumor DNA (ctDNA) as a biomarker for solid tumor malignancies. ctDNA can provide real-time insights on patient response or disease progression, support patient prognostic stratification, and enable early detection of residual disease, the company says. The enhanced assay, which received Clinical Laboratory Improvement Amendments (CLIA) approval, features a flexible patient-specific panel design of between 18 and 50 variants, demonstrating a sensitivity of >99% for detecting ctDNA at variant allele frequencies as low as 0.005%, the company says. In addition, the company has also received CLIA approval on the whole exome sequencing component of PCM as a stand-alone comprehensive genomic profiling (CGP) assay to permit reporting of tumor profiles. I Product Launches
Microbioz India, November 2023| 40 Further reading: Invitae’s Personalized Cancer Monitoring Assay Gets First Commercial Coverage Compared to the prior version, the enhanced assay permits a new lower mass input limit that results in the same sensitivity as the prior version with less cell-free DNA (cfDNA), enabling Invitae to test samples that might have been previously rejected. The enhanced assay also involves fewer steps that will increase capacity and reduce the burden of materials and labor costs. Lastly, the enhanced chemistry is automation friendly enabling scale and supporting future growth. “This focused launch and enhanced chemistry will enable biopharma partners to detect recurring disease early,” says Bob Daber, PhD, chief scientific officer of Invitae. “This will potentially help set MRD as a standard practice in clinical studies and increase the velocity of drug development. Our vision is that insights gained from Invitae Personalized Cancer Monitoring will lead to research breakthroughs that positively influence patient journeys.” Roche Expands HPV Testing for Cobas 5800 Molecular System Story source/Credit: Roche oche announced the U.S. Food and Drug Administration (FDA) approved the cobas HPV test for use on its next-generation cobas 5800 molecular instrument. This new approval is designed to broaden access to HPV testing in mid-size and smaller labs in the U.S. to help enable accurate and timely diagnosis of patients who are at risk of developing cervical cancer. With the addition of HPV testing, the cobas 5800 supports critical molecular-testing needs with a broad portfolio of infectious disease, sexual health, respiratory, and transplant solutions, the company says. “Roche’s continued menu expansion of tests like these for use on the cobas 5800 supports our ongoing commitment to provide access to highmedical-value solutions that can help clinicians deliver the best patient care,” says Whitney Green, senior vice president, Molecular & Pathology Lab at Roche Diagnostics. “Expanding access to HPV testing on our new 5800 platform will enable more labs to deliver accurate and reliable results that can lead to the earlier diagnosis of cervical cancer.” The cobas HPV Test The cobas HPV test is indicated for use for routine cervical-cancer screening as per professional medical guidelines, including triage of ASC-US cytology, co-testing (or adjunctive screen) with cytology, and HPV primary screening of women to assess the risk for cervical precancer and cancer. The cobas 5800 supports loading primary-collection vials directly onto the compact system, minimizing hands-on time. The cobas HPV test, originally introduced in 2011 and clinically validated in large, FDA-registrational trials, ATHENA on the cobas 4800 and IMPACT on the cobas 6800/8800, helps healthcare providers identify women at risk for cervical cancer by individually identifying the presence of the DNA of HPV genotypes 16 and 18—the two genotypes responsible for about 70% of all cervical cancers(1)—and reporting the 12 other high-risk HPV types as a combined result, all in one test and from one patient sample. The cobas 5800 System The cobas 5800 System is a real-time molecular solution built upon the proven technology platform of the cobas 6800/8800 Systems. The cobas 5800 is designed to provide optimized workflow efficiencies, simplicity and timely results to meet the changing demands of labs of all sizes. Labs are able to test multiple assays simultaneously and receive up to 144 results in an eight-hour shift. R Product Launches
Microbioz India, November 2023| 41 The cobas HPV test is now part of the comprehensive menu of assays for use on the cobas 5800, including cobas BKV, cobas CMV, cobas EBV, cobas HBV, cobas HBV RNA (RUO), cobas HCV, cobas HIV-1, cobas HIV-1/HIV-2 Qual, cobas SARS-CoV-2 Qual, cobas CT/NG, cobas TV/MG, and cobas omni Utility Channel (a dedicated open channel). This comprehensive, high-medical-value menu is now available across all of Roche’s flagship molecular platforms, including cobas 5800, 6800, and 8800. Featured image: The cobas 5800. Photo: Roche References: (1) Li N, Franceschi S, Howell‐Jones R, Snijders PJF, Clifford GM. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer. 2011;128(4):927–35. Modelling Enables Breakthroughs in Neuromuscular Disease Research Story source/Credit: AMS Biotechnology (Europe) Ltd CELLBANKER® series of cell freezing media offer high cell viability (>90%) in serum, serumfree, GMP and DMSO-free formats AMSBIO has published a case study that describes how a team of scientists, led by Dr. Roger Kamm from the Massachusetts Institute of Technology (MIT), has developed a protocol for the fabrication of a 3D microfluidic neuromuscular platform that can be used to model Motor Neuron Diseases (MND’s). or one of the most fatal types of MND, amyotrophic lateral sclerosis (ALS), patients have a life expectancy of only 2 to 5 years. Despite widespread research efforts, effective treatments for MNDs remain elusive, largely due to the complex nature of these diseases and a lack of in-depth understanding of their underlying mechanisms. Researchers at MIT have developed novel approaches to unravel the pathogenesis of MNDs using CELLBANKER® 1 and STEMCELLBANKER® cryopreservation media from AMSBIO. These new developments hold significant promise in revolutionizing the approach to drug discovery and better understanding the development of MNDs. Dr. Kamm said “Traditional drug discovery methods for MNDs have often disregarded the role of skeletal muscle cells, focusing predominantly on their effect on motor neurons. However, our new 3D neuromuscular model offers a broader view of the pathology and presents a novel avenue for uncovering effective treatments targeting both motor neurons and muscle cells, that address the complex nature of MNDs”. He added “Our protocol describes a development of a new microfluidic chip that contains compartments for each cell type, allowing for the separation of the motor neuron and muscle cell cultures to mimic the physiology found in living tissue. Induced pluripotent stem cells (iPSCs) from either healthy donors or ALS patients were differentiated into neural stem cells, which were expanded and cryogenically preserved using STEMCELLBANKER® from AMSBIO. Using our innovative approach shows great promise to help tailor treatments to an individual’s genetics and consequent drug response to enhance their effectiveness while minimising side effects. By providing a more accurate representation of the disease, the 3D neuromuscular model could accelerate drug discovery and streamline the transition from laboratory research to clinical applications”. F Product Launches
Microbioz India, November 2023| 42 VIEW CASE STUDY The CELLBANKER® series of cell freezing media from AMSBIO allow the stable long-term storage of cells. With its unique formulation which enables stable cryopreservation and high viability after freezethaw procedures, CELLBANKER® and STEM-CELLBANKER® are trusted solution for the storage of any cell type including sensitive cell lines. Available in several formulations, this series of easy-to-use cell freezing media offers high cell viability (>90%) in serum, serum-free, GMP and DMSO-free formats. VIEW PRODUCT INFORMATION About AMS Biotechnology Founded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading transatlantic company contributing to the acceleration of discovery through the provision of cutting-edge life science technology, products, and services for R&D in the medical, nutrition, cosmetics, and energy industries. AMSBIO has in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion, and proliferation. This expertise in cell culture and the ECM allows AMSBIO to partner with clients in tailoring cell systems to enhance organoid and spheroid screening outcomes using a variety of 3D culture systems, including organ-on-a-chip microfluidics. For drug discovery research, AMSBIO offers assays, recombinant proteins, and cell lines. Drawing upon a huge and comprehensive biorepository, AMSBIO is widely recognized as a leading provider of high-quality tissue specimens (including custom procurement) from both human and animal tissues. The company provides unique clinical grade products for stem cells and cell therapy applications. This includes GMP cryopreservation technology, and high-quality solutions for viral delivery. Cytomos selected to showcase CDS cell analysis technology at BIA’s BioProcessUK Dragon’s Den session Story source/Credit: Cytomos Biotech company, Cytomos is pleased to announce that it has been selected to showcase its dielectric spectroscopy (CDS) platform at the BIA’s BioProcess UK Dragon’s Den special session focused on next generation analytical technologies, taking place on day two of this year’s annual conference: 30 November. ytomos’ CSO, Dr. Lindsay Fraser, will highlight the benefits and full potential of Cytomos’ transformative CDS technology and take questions from inquisitive delegates. Chaired by Julie Kerby, Managing Director of Technology and Process Innovation, Cell and Gene Therapy Catapult, the event will feature technologies from eight pre-selected companies. C Product Launches
Microbioz India, November 2023| 43 CDS is securing increased industry recognition as a technological innovation that provides information on cell properties that no other process analytical technology (PAT) can. The capability to collect a multitude of data that measures the intrinsic properties of individual cells in real-time, and to obtain a unique profile for subsequent downstream analysis and characterisation, is set to radically change the way that processes are monitored, whilst transforming velocity in biopharmaceutical R&D and fundamentally changing bioprocess PAT adaptation. The winning technology will be announced at the event post the presentations. Commenting on her upcoming presentation, Dr Lindsay Fraser stated: “I am really pleased that our technology has been pre-selected – with my innate passion for life science development, I am looking forward to the opportunity to highlight the key features and range of novel benefits that our advanced technology brings to researchers, scientists and industrialists in both the biologics and cell and gene therapy sectors.” Dr Fraser will explain how the fast and scalable CDS platform closely monitors a broad range of individual cell features simultaneously, to provide label-free, unbiased, consistent, accurate and reliable predictive analytics for biomanufacturing and other applications. A deep dive into industry benefits will include featuring how the novel technology can save and optimise batches, addressing pressing industry needs for smarter, less labour-intensive, and more automated processes capable of driving down biomanufacturing costs as well as realising scale-out in the manufacture of personalised, regenerative medicines. “I will show how harnessing the power of dielectric spectroscopy and our proprietary silicon chip sensors enables the R&D community to generate unique fingerprints to characterise cells without the requirement for labels. Our platform improves the pace and accuracy of single cell analysis. It has the potential to be incorporated in-line, allowing realtime monitoring of cell manufacturing events and predicting manufacturing success. Moreover, we are keen to reemphasise that the technology is compatible – an asset that is usable both on its own or alongside flow cytometry technologies”, she continued. Cytomos CEO, David Rigterink added, “BioprocessUK – with its audience of investors and potential collaborators and partners – provides an ideal conference platform for bringing our CDS technology even more into industry focus. The technology has huge scope to serve as a transformative enabler for R&D: providing industry with a tool for making critical decisions much earlier and bringing novel therapies to market significantly faster. Our ultimate strategy is to construct digital twins and high throughput process automation – with CDS making viable the delivery of more therapies to patients: thereby improving healthcare”. About Cytomos and CDS Cytomos is a dynamic early-stage company developing ground-breaking cell analysis systems that can be used alone or alongside conventional technologies such as flow cytometry. Cytomos Dielectric Spectroscopy (CDS) leverages costefficient microchip technology, providing streamlined testing strategies and economically viable cell therapies. The technology closely monitors a broad range of individual cell features simultaneously and collects data on intrinsic cellular properties in real-time, delivering unbiased, consistent, accurate and reliable predictive analytics for biomanufacturing and other applications. Revvity and SCIEX Collaborate to Provide Innovative Neonatal Mass Spectrometry Solution Story source/Credit: Revvity, Inc Offering combines Revvity’s market leading reagents with SCIEX precise innovative MS/MS for labs looking to expand newborn screening capabilities evvity, Inc. announces a value-added distribution agreement with SCIEX, a global leader in life science analytical technologies. R Product Launches
Microbioz India, November 2023| 44 This strategic agreement is aimed at advancing mass spectrometry solutions in Revvity's newborn screening products and the anticipated solution combines Revvity’s expertise and resources with SCIEX’s innovative mass spectrometry solutions. With this agreement, Revvity hopes to further help laboratories identify newborn babies with a range of rare disorders, from lysosomal storage disorders to amino acid disorders. Mass spectrometry is a fundamental tool in expanded newborn screening and has seen remarkable growth over the years. Revvity will combine SCIEX mass spectrometers with Revvity’s NeoBase™ 2 and NeoLSD™ reagents to support this growth even further by enhancing the robustness and precision of mass spectrometry analyses for newborn screening. Expanded newborn screening techniques such as mass spectrometry are fundamental in discovering babies with rare, but treatable conditions, such as lysosomal storage conditions, as early as possible. Currently, over 40 conditions can be screened for using mass spectrometry, and this collaboration hopes to advance the precision and robustness of this screening. “Revvity is committed to advancing newborn screening and helping give babies a better start in life,” said Petra Furu, general manager, reproductive health, Revvity. “This capability will help provide our customers with the best options for their expanded screening programs by combining precise instrumentation with groundbreaking reagents.” To learn more about Revvity’s range of solutions for newborn screening, visit this webpage. About Revvity At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. With 2022 revenue of more than $3 billion and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 190 countries. About SCIEX SCIEX empowers our customers to solve the most impactful analytical challenges in quantitation and characterization. With groundbreaking innovation and outstanding reliability and support, SCIEX has been at the forefront of the field for over 50 years. Since the launch of the first-ever commercially successful triple quadrupole in 1981, we continue to develop technologies and solutions that influence life-changing research and outcomes. That’s why thousands of life science experts around the world choose SCIEX to get the answers they can trust. Advances in human wellness depend on the power of precise science. SCIEX is proud to be part of Danaher. Danaher is a global science and technology leader. Together, we combine our capabilities to accelerate the real-life impact of tomorrow’s science and technology to improve human health. Product Launches
Microbioz India, November 2023| 45
Microbioz India, November 2023| 46
Microbioz India, November 2023| 47
Microbioz India, November 2023| 48 PUBLISHED ON: 25th November 2023 RNI NUMBER: UPENG/2017/73675